Drug “Clicking” on Cell-Penetrating Fluorescent Nanoparticles for In Cellulo Chemical Proteomics
Open Access
- 18 August 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 29 (9) , 3154-3160
Abstract
Chemical proteomics approaches are widely used to identify molecular targets of existing or novel drugs. This manuscript describes the development of a straightforward approach to conjugate azide-labeled drugs via click chemistry to alkyne-tagged cell-penetrating fluorescent nanoparticles as a novel tool to study target engagement and/or identification inside living cells. A modification of the Baeyer test for alkynes allows monitoring the Cu(I)-catalyzed azide–alkyne cycloaddition (CuAAC) reaction, guaranteeing the presence of the drug on the solid support. As a proof of concept, the conjugation of the promiscuous kinase inhibitor dasatinib to Cy5-labeled nanoparticles is presented. Dasatinib-decorated fluorescent nanoparticles efficiently inhibited its protein target SRC in vitro, entered cancer cells, and colocalized with SRC in cellulo.Keywords
Funding Information
- Engineering and Physical Sciences Research Council (EP/N021134/1)
- FP7 People: Marie-Curie Actions (267226, 294142)
- Ministerio de Economía y Competitividad (PTQ-13-06046)
- Universidad de Granada (CEI2015-MP-BS48)
- Ministerio de Educación, Cultura y Deporte (FPU14/02181)
This publication has 34 references indexed in Scilit:
- Opportunities and challenges in phenotypic drug discovery: an industry perspectiveNature Reviews Drug Discovery, 2017
- Next-Generation Phenotypic ScreeningFuture Medicinal Chemistry, 2016
- The discovery of first-in-class drugs: origins and evolutionNature Reviews Drug Discovery, 2014
- The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patientsJournal of Cancer Research and Clinical Oncology, 2013
- Target identification and mechanism of action in chemical biology and drug discoveryNature Chemical Biology, 2013
- Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma StrategyJournal of Medicinal Chemistry, 2012
- In Situ Monitoring of Bindings between Dasatinib and Its Target Protein Kinases Using Magnetic Nanoparticles in Live CellsJournal of the American Chemical Society, 2008
- Target profiling of small molecules by chemical proteomicsNature Chemical Biology, 2008
- Target deconvolution strategies in drug discoveryNature Reviews Drug Discovery, 2007
- 2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure−Activity Relationship Studies toward the Discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan-Src Kinase InhibitorJournal of Medicinal Chemistry, 2006